amiodarone has been researched along with American Trypanosomiasis in 18 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Accordingly, amiodarone, an inexpensive and extensively- used class III antiarrhythmic has been proposed as a treatment for Chagas' disease and leishmaniasis." | 8.02 | The Rationale for Use of Amiodarone and its Derivatives for the Treatment of Chagas' Disease and Leishmaniasis. ( Benaim, G; Paniz-Mondolfi, AE; Sordillo, EM, 2021) |
| "4 mg/lb], PO, q 24 h, with or without a loading dosage protocol) and itraconazole (approx 10 mg/kg [4." | 5.51 | Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs. ( Benaím, G; Estep, JS; Luis Concepción, J; Madigan, R; Majoy, S; Márquez, ME; Mogollón-Mendoza, AC; Paniz-Mondolfi, AE; Pérez Alvarez, A; Ritter, K; Rodriguez-Morales, AJ; Silva, SC; Zao, CL, 2019) |
| " We compared 72 patients with long-term use (11 +/- 5 years) of amiodarone, including 22 patients who developed goiter, to 33 patients who did not use amiodarone, followed-up for 2 to 20 years (7 +/- 11 years)." | 5.32 | Impact of long-term administration of amiodarone on the thyroid function of patients with Chagas' disease. ( Fernandes, GA; Guariento, ME; Maciel, RM; Silva, JR; Ward, LS, 2004) |
| " Accordingly, amiodarone, an inexpensive and extensively- used class III antiarrhythmic has been proposed as a treatment for Chagas' disease and leishmaniasis." | 4.02 | The Rationale for Use of Amiodarone and its Derivatives for the Treatment of Chagas' Disease and Leishmaniasis. ( Benaim, G; Paniz-Mondolfi, AE; Sordillo, EM, 2021) |
| " Thus, the aim of this work was to determine the Th1/Th17 (IL-6, IL-2, TNF, IL-17 and IFN-γ) and Th2 (IL-4 and IL-10) serum profile in Venezuelan Chagasic patients stratified according amiodarone treatment, hypertension and arrhythmias." | 3.85 | Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status. ( Fresno, M; Gironès, N; Marques, J; Mendoza, I; Mijares, A; Rodríguez-Angulo, H; Villegas, M, 2017) |
| "Amiodarone is also capable to inhibit the oxidosqualene cyclase, a key enzyme in the synthesis of ergosterol." | 2.47 | Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. ( Benaim, B; Garcia, CR, 2011) |
| "4 mg/lb], PO, q 24 h, with or without a loading dosage protocol) and itraconazole (approx 10 mg/kg [4." | 1.51 | Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs. ( Benaím, G; Estep, JS; Luis Concepción, J; Madigan, R; Majoy, S; Márquez, ME; Mogollón-Mendoza, AC; Paniz-Mondolfi, AE; Pérez Alvarez, A; Ritter, K; Rodriguez-Morales, AJ; Silva, SC; Zao, CL, 2019) |
| "Chagas disease is a neglected tropical affection caused by the protozoan parasite Trypanosoma cruzi." | 1.48 | Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure. ( Benaim, G; Hejchman, E; Hernández-Rodríguez, V; Pinto-Martinez, A; Rodríguez-Durán, J, 2018) |
| "Dronedarone is an amiodarone derivative in which the 2,5-diiodophenyl moiety of the parental drug has been replaced with an unsubstituted phenyl group aiming to eliminate the thyroid toxicity frequently observed with amiodarone treatment." | 1.38 | In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. ( Benaim, G; Garcia-Marchan, Y; Hernandez-Rodriguez, V; Mujica-Gonzalez, S; Paniz-Mondolfi, A; Parra-Gimenez, N; Plaza-Rojas, L; Silva, ML; Uzcanga, G, 2012) |
| "Stroke was more frequent in CD (15." | 1.33 | Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort. ( Faiçal, F; Oliveira-Filho, J; Reis, FJ; Torreão, JA; Viana, LC; Vieira-de-Melo, RM; Villar, FA, 2005) |
| " We compared 72 patients with long-term use (11 +/- 5 years) of amiodarone, including 22 patients who developed goiter, to 33 patients who did not use amiodarone, followed-up for 2 to 20 years (7 +/- 11 years)." | 1.32 | Impact of long-term administration of amiodarone on the thyroid function of patients with Chagas' disease. ( Fernandes, GA; Guariento, ME; Maciel, RM; Silva, JR; Ward, LS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Benaim, G | 6 |
| Sanders, JM | 1 |
| Garcia-Marchán, Y | 2 |
| Colina, C | 1 |
| Lira, R | 1 |
| Caldera, AR | 1 |
| Payares, G | 1 |
| Sanoja, C | 1 |
| Burgos, JM | 1 |
| Leon-Rossell, A | 1 |
| Concepcion, JL | 2 |
| Schijman, AG | 1 |
| Levin, M | 1 |
| Oldfield, E | 1 |
| Urbina, JA | 1 |
| Engel, JC | 1 |
| Ang, KK | 1 |
| Chen, S | 1 |
| Arkin, MR | 1 |
| McKerrow, JH | 1 |
| Doyle, PS | 1 |
| Barbosa, JMC | 2 |
| Pedra Rezende, Y | 1 |
| de Melo, TG | 2 |
| de Oliveira, G | 1 |
| Cascabulho, CM | 1 |
| Pereira, ENGDS | 1 |
| Daliry, A | 2 |
| Salem, KS | 1 |
| Pedra-Rezende, Y | 1 |
| Pereira, LD | 1 |
| Barbosa, HS | 1 |
| Lannes-Vieira, J | 1 |
| de Castro, SL | 1 |
| Salomão, K | 1 |
| Paniz-Mondolfi, AE | 4 |
| Sordillo, EM | 2 |
| Martinez-Sotillo, N | 1 |
| Rodríguez-Angulo, H | 1 |
| Marques, J | 1 |
| Mendoza, I | 1 |
| Villegas, M | 1 |
| Mijares, A | 1 |
| Gironès, N | 1 |
| Fresno, M | 1 |
| Pinto-Martinez, A | 1 |
| Hernández-Rodríguez, V | 2 |
| Rodríguez-Durán, J | 1 |
| Hejchman, E | 1 |
| Madigan, R | 2 |
| Majoy, S | 1 |
| Ritter, K | 1 |
| Luis Concepción, J | 1 |
| Márquez, ME | 1 |
| Silva, SC | 1 |
| Zao, CL | 2 |
| Pérez Alvarez, A | 1 |
| Rodriguez-Morales, AJ | 1 |
| Mogollón-Mendoza, AC | 1 |
| Estep, JS | 1 |
| Yang, YC | 1 |
| Tomanek, L | 1 |
| Cooke, A | 1 |
| Berger, R | 1 |
| Chien, LC | 1 |
| Carmo, AA | 1 |
| Rocha, MO | 1 |
| Silva, JL | 1 |
| Ianni, BM | 1 |
| Fernandes, F | 1 |
| Sabino, EC | 1 |
| Ribeiro, AL | 1 |
| Bestetti, R | 1 |
| Cardinalli-Neto, A | 1 |
| Pérez-Alvarez, AM | 1 |
| Lanza, G | 1 |
| Márquez, E | 1 |
| Benaim, B | 1 |
| Garcia, CR | 1 |
| Mujica-Gonzalez, S | 1 |
| Plaza-Rojas, L | 1 |
| Silva, ML | 1 |
| Parra-Gimenez, N | 1 |
| Paniz-Mondolfi, A | 1 |
| Uzcanga, G | 1 |
| Silva, JR | 1 |
| Guariento, ME | 1 |
| Fernandes, GA | 1 |
| Maciel, RM | 1 |
| Ward, LS | 1 |
| Oliveira-Filho, J | 1 |
| Viana, LC | 1 |
| Vieira-de-Melo, RM | 1 |
| Faiçal, F | 1 |
| Torreão, JA | 1 |
| Villar, FA | 1 |
| Reis, FJ | 1 |
| Leite, SA | 1 |
| Leite, PJ | 1 |
| Rocha, GA | 1 |
| Routledge, PA | 1 |
| Bittencourt, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Trial Testing Amiodarone in Chagas Cardiomyopathy (ATTACH)[NCT03193749] | Phase 3 | 200 participants (Anticipated) | Interventional | 2017-06-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amiodarone and American Trypanosomiasis
| Article | Year |
|---|---|
Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target Against
Topics: Amiodarone; Calcium; Chagas Disease; Homeostasis; Humans; Trypanosoma cruzi | 2020 |
Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Topics: Amiodarone; Antiprotozoal Agents; Calcium; Chagas Disease; Homeostasis; Humans; Leishmania; Leishman | 2011 |
1 trial available for amiodarone and American Trypanosomiasis
| Article | Year |
|---|---|
Carbamazepine kinetics in cardiac patients before and during amiodarone.
Topics: Adult; Aged; Amiodarone; Carbamazepine; Chagas Disease; Drug Interactions; Drug Therapy, Combination | 1994 |
15 other studies available for amiodarone and American Trypanosomiasis
| Article | Year |
|---|---|
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
Topics: Acute Disease; Amiodarone; Animals; Calcium; Chagas Disease; Chlorocebus aethiops; Crystallography, | 2006 |
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Topics: Animals; Cattle; Cell Line; Cell Line, Tumor; Chagas Disease; Drug Evaluation, Preclinical; Hepatocy | 2010 |
Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
Topics: Amiodarone; Animals; Chagas Disease; Disease Models, Animal; Drug Therapy, Combination; Heart; Heart | 2022 |
Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in
Topics: Amiodarone; Chagas Disease; Cytoskeleton; Humans; Nitroimidazoles; Trypanocidal Agents; Trypanosoma | 2022 |
The Rationale for Use of Amiodarone and its Derivatives for the Treatment of Chagas' Disease and Leishmaniasis.
Topics: Amiodarone; Animals; Calcium; Chagas Disease; Dogs; Leishmaniasis; Trypanocidal Agents; Trypanosoma | 2021 |
Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Arrhythmias, Cardiac; Biomarkers; Chagas Disease; Cyt | 2017 |
Anti-Trypanosoma cruzi action of a new benzofuran derivative based on amiodarone structure.
Topics: Amiodarone; Animals; Benzofurans; Calcium; Chagas Disease; Chlorocebus aethiops; Dose-Response Relat | 2018 |
Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs.
Topics: Amiodarone; Animals; Chagas Disease; Dog Diseases; Dogs; Itraconazole; Louisiana; Texas; Trypanosoma | 2019 |
PCR monitoring of parasitemia during drug treatment for canine Chagas disease.
Topics: Amiodarone; Animals; Chagas Disease; DNA, Kinetoplast; DNA, Protozoan; DNA, Satellite; Dog Diseases; | 2019 |
Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Chagas Disease; Female; Humans; Male; Middle Aged; Parasi | 2015 |
Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Chagas Disease; Chronic Disease; | 2009 |
Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chagas Disease; Chronic Disease; Drug Therapy, Combinat | 2009 |
In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.
Topics: Amiodarone; Calcium; Chagas Disease; Dronedarone; Membrane Potential, Mitochondrial; Trypanosoma cru | 2012 |
Impact of long-term administration of amiodarone on the thyroid function of patients with Chagas' disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chagas Disease; Echocardiography; Electrocardiography; Electroca | 2004 |
Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Chagas Disease; Cohort Studies; Fem | 2005 |